Loading clinical trials...
Loading clinical trials...
An Open-label Extension to the Phase 2 Randomized, Double-blind, Placebo-controlled, Crossover Multicenter Study to Evaluate the Safety and Efficacy of KZR-616 in the Treatment of Patients With Active Polymyositis or Dermatomyositis
Conditions
Interventions
KZR-616
Locations
10
United States
KZR Research Site
Beverly Hills, California, United States
KZR Research Site
Orange, California, United States
KZR Research Site
Miami, Florida, United States
KZR Research Site
Kansas City, Kansas, United States
KZR Research Site
Baltimore, Maryland, United States
KZR Research Site
Ann Arbor, Michigan, United States
Start Date
November 4, 2020
Primary Completion Date
March 10, 2023
Completion Date
June 12, 2023
Last Updated
November 19, 2025
NCT00017914
NCT07089121
NCT04402086
NCT07160205
NCT07374107
NCT07265999
Lead Sponsor
Kezar Life Sciences, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions